Pouillart P, Palangie T, Jouve M, Beuzeboc P, Dorval T, Garcia-Giralt E, Asselain B
Pathol Biol (Paris). 1987 Jan;35(1):103-10.
The clinical results achieved for more than 10 years in patients with metastatic breast cancer have clearly demonstrated the efficacy of chemotherapy programs including Adriamycin. This therapeutic effect was confirmed when it is given in protocols of adjuvant chemotherapy. Some complementary studies have demonstrated 4 points in order to define the better modality of application of Adriamycin: the results of induction chemotherapy's protocols are not better if the treatment is given beyond 6 months, the alternative administration of 2 noncross resistant programs of chemotherapy is no more efficient than the continuous administration of a program of chemotherapy including Adriamycin, the increase of the doses of cytotoxic chemotherapy does not change the median of survival of the patients, the fractionated administration of Adriamycin is as effective as the conventional administration of the same total dose.
在转移性乳腺癌患者中超过10年所取得的临床结果已清楚地证明了包括阿霉素在内的化疗方案的疗效。当它用于辅助化疗方案时，这种治疗效果得到了证实。一些补充研究已阐明了4点，以便确定阿霉素更好的应用方式：如果治疗时间超过6个月，诱导化疗方案的结果并不会更好；交替使用2种非交叉耐药的化疗方案并不比持续使用包括阿霉素的化疗方案更有效；增加细胞毒性化疗的剂量并不会改变患者的生存中位数；阿霉素的分次给药与相同总剂量的传统给药一样有效。
